Quantifying systemic absorption of topical hydrocortisone in erythroderma

Systemic absorption of topical medications remains poorly understood in patients with widespread skin conditions. Prior research has shown that barrier function is compromised in erythroderma, but the extent of drug absorption is unclear. No prior work had resolved the pharmacokinetic profile of hydrocortisone in such patients. This gap motivated the current investigation into systemic absorption patterns. Established knowledge includes typical topical corticosteroid use for localized inflammation. However, the role of systemic exposure in erythroderma is less defined. This paper's contribution lies in quantifying absorption rates in a clinical cohort. The findings may help refine dosing strategies for topical corticosteroids.

The study aimed to measure systemic absorption of hydrocortisone in patients with erythroderma. Researchers focused on comparing topical versus intravenous drug exposure. The goal was to determine if topical application leads to pharmacologically relevant plasma levels. This problem is significant because systemic corticosteroid effects can cause adverse outcomes. Prior assumptions suggested minimal absorption, but evidence was lacking. The motivation came from clinical concerns about drug safety in erythroderma. The study sought to clarify whether topical use results in measurable systemic concentrations. These data could inform safer treatment protocols for affected patients.

Researchers used a pharmacokinetic approach to compare absorption routes. They measured plasma concentration over 24 hours following both topical and intravenous HC administration. The study involved seven patients diagnosed with erythroderma. Blood samples were collected at defined intervals for analysis. The area under the curve was calculated for each administration method. The ratio of these areas provided absorption estimates. Total HC absorbed was determined by integrating concentration-time data. The methodology ensured precise quantification of systemic exposure.

Systemic absorption of HC ranged from 19 to 93 mg over 24 hours. This corresponded to 4-19% of the 500 mg topical dose administered. The highest absorption rate reached nearly 20% of the applied dose. Plasma concentration curves showed significant systemic availability. The intravenous-to-topical AUC ratio indicated substantial absorption. These findings suggest that topical HC reaches pharmacologically active levels. The observed range reflects variability among patients with erythroderma. The results challenge assumptions about minimal systemic effects of topical corticosteroids.

The authors propose that topical HC in erythroderma leads to significant systemic exposure. They suggest that this absorption level may have pharmacological consequences. The study's findings trace to the measured AUC ratios and plasma concentrations. No claims about long-term effects or treatment guidelines are made. The authors emphasize the need for caution in dosing decisions. They do not assert that systemic effects are always harmful or predictable. The study's implications are limited to the observed absorption rates. These results may inform future clinical management of corticosteroid use in erythroderma.